Dr. Keith Ablow, Founder of The Ablow Cetner offering the Pain-2-Power coaching program The first Pain-2-Power Person of the Week is Michael van der Veen, Dr. Ablow wrote. Attorney van der Veen was one of President Donald Trump s lawyers at his second impeachment trial. He doesn t just take on clients the political Right would necessarily embrace. He has represented those seeking to provide clean needles to drug users in an effort to combat HIV/AIDS. He has represented clients alleging police brutality. He also represented a client suing President Trump for what the client alleged were baseless claims that the U.S. Postal Service was involved in voter fraud.
Healthcare industry professionals Ron Greeno and Mike Murphy join CLEW Medical s Advisory Board
USA - English
News provided by
Share this article
Share this article
TEL AVIV, Israel and WILMINGTON, Delaware, Feb. 17, 2021 /PRNewswire/ CLEW Medical has announced that Dr. Ron Greeno and Michael W. Murphy have joined the company s Advisory Board. CLEW Medical will benefit from their extensive experience and background in the healthcare industry as a vital part of the company s plans for North American expansion and commercialization.
Following recent FDA approval of the CLEWICU solution, Dr. Greeno and Mr. Murphy will work to guide CLEW and expand the company s footprint in North America, offering their professional insights and advice as the company extends its solution to additional care settings.
President Charles Savarin is First Dominican to Receive Vaccination as Nation Prepares Mass Rollout
News provided by
Share this article
Share this article
LONDON, Feb. 17, 2021 /PRNewswire/ After receiving 70,000 vaccination doses from India, the Commonwealth of Dominica has begun rolling out its doses with President Charles Savarin being the first Dominican to take the vaccine last Friday. The AstraZeneca COVID-19 vaccine will be distributed in a mass rollout on the island, planned by the Ministry of Health, anticipated to begin on February 22
nd.
Dominica is one of the nations least impacted by the coronavirus, recording zero deaths since the outbreak. Despite the pandemic, the administration has ensured that national development projects continue to progress while also guaranteeing the financial protection of its citizens with $12.7 million invested in COVID-19 relief efforts.
Bionomics Limited (ASX: BNO,OTCQB: BNOEF, Germany: AU000000BNO5) (
Bionomics) today announced that it has entered into a Memorandum of Understanding with EmpathBio Inc (
EmpathBio), a wholly owned subsidiary of Germany-based CNS clinical development company, atai Life Sciences (
atai). Under the Memorandum of Understanding, Bionomics and EmpathBio propose to collectively explore a combination drug treatment regimen with Bionomics BNC210 and EmpathBio s 3,4-Methylenedioxymethamphetamine (MDMA) derivative EMP-01. The parties will explore whether the different mechanisms of action of EMP-01 and BNC210 may offer the potential for developing an improved treatment regimen for the treatment of Post-Traumatic Stress Disorder (PTSD).
BNC210 is Bionomics lead drug candidate, which has been granted Fast Track designation by the US Food and Drug Administration (FDA) for the treatment of PTSD and other trauma-related and stress-related disorders. A new solid dose formulation of BNC210 ha